This past June, the American Medical Association (AMA) joined myriad other consumer and medical interest groups to ask the question whether direct-to-consumer (DTC) advertising by pharmaceutical companies had gotten out
Debate on DTC Advertising Heats Up!
Introduction to this Special Issue: This past June, the American Medical Association (AMA) joined myriad other consumer and medical interest groups to ask the question whether direct-to-consumer (DTC) advertising by pharmaceutical companies had gotten out of hand. Sensing the way the winds were blowing, the pharmaceutical industry's trade group PhRMA (Pharmaceutical and Research Manufacturers of America) announced on Aug. 2 that it would self-police DTC drug advertising practices by signing up pharmaceutical manufacturers to a voluntary agreement to follow PhRMA's new DTC policies. In this issue, we will look at those policies and at the reactions they caused in the medical, legislative and consumer communities.
This premium content is locked for LawJournalNewsletters subscribers only
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN LawJournalNewsletters
- Stay current on the latest information, rulings, regulations, and trends
- Includes practical, must-have information on copyrights, royalties, AI, and more
- Tap into expert guidance from top entertainment lawyers and experts
Already have an account? Sign In Now
For enterprise-wide or corporate access, please contact Customer Service at [email protected] or call 1-877-256-2473.






